TEVA

Herzuma® (trastuzumab) (Celltrion / Teva) (September-2019)Ranopto® (ranibizumab) (Bioeq / Teva) (December-2023)Teva-teriparatide (teriparatide) (Teva) (June-2020)

Biosimilars Approved In The E.U.

Ongavia (ranibizumab) (Teva / Bioeq) (May-2022 in the United Kingdom) Ovaleap (follitropin alfa/beta) (Teva Pharma) (September-2013)Ranivisio (ranibizumab) (Teva / Bioeq) (August-2022)Tevagrastim (filgrastim) (Teva Generics) (September-2008)

Biosimilars Approved In Australia

Tevagrastim (filgrastim) (Teva Pharma Australia) (August-2011)

Biosimilars Approved In Japan

Filgrastim BS (filgrastim) (Teva Pharma Japan / Nippon Kayaku) (February-2013)

Inter Partes Review Proceedings

AJOVY / EMGALITYIPR2018-01422
IPR2018-01423
IPR2018-01424
IPR2018-01425
IPR2018-01426
IPR2018-01427
IPR2018-01710
IPR2018-01711
IPR2018-01712
IPR2022-00738
IPR2022-00739
IPR2022-00796
HERCEPTIN / HERZUMAIPR2017-01121
IPR2017-01122
IPR2017-01139
IPR2017-01140
IPR2017-01373
IPR2017-01374
RITUXAN / TRUXIMAIPR2016-01614
IPR2016-01667
IPR2017-01093
IPR2017-01094
IPR2017-01095
IPR2017-01227
IPR2017-01229
IPR2017-01230
IPR2018-01019

U.S. Patent Litigations

FORTEO1:16-cv-00596 (S.D. Ind.)
AJOVY / EMGALITY1:17-cv-12087 (D. Mass.)
1:18-cv-10242 (D. Mass.)
1:18-cv-12029 (D. Mass.)
1:21-cv-10954 (D. Mass.)
GRANIX / NEUPOGEN / NEULASTA2:13-cv-04911 (D.N.J.)
HERCEPTIN / HERZUMA / GENENTECH CABILLY1:18-cv-00095 (D. Del.)
1:18-cv-01025 (D. Del.)
4:18-cv-00274 (N.D. Cal.)
RITUXAN / TRUXIMA / GENENTECH CABILLY1:18-cv-00574 (D.N.J.)
1:18-cv-11553 (D.N.J.)
4:18-cv-00276 (N.D. Cal.)

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.